Work

Development of a genetic priority score to predict drug side effects using human genetic evidence

Year: 2025

Type: article

Abstract: Many drug failures in clinical trials are due to inadequate safety profiles. We developed an in-silico side effect genetic priority score (SE-GPS) that leverages human genetic evidence to inform side effect risk for a given drug target. We construct the SE-GPS in the Open Target dataset using post-marketing side effect data, externally test it in OnSIDES using side effects reported from drug labels and then generate a SE-GPS for 19,422 protein coding genes and 502 phecodes, of which 1.7% had a SE-GPS > 0. To consider drug mechanism, we incorporated the direction of genetic effect into a directional version of the score called the SE-GPS-DOE. We observe that restricting to at least two lines of genetic evidence conferred a 2.3- and 2.5-fold increased risk in side effects in Open Targets and OnSIDES respectively, with increased enrichments in severe drugs. We make all predictions publicly available in a web portal. Here the authors develop a genetic priority score to predict side effects by integrating multiple lines of genetic evidence. By applying this score, they provide evidence of known side effects and suggest ones with no clinical trial evidence.

Source: Nature Communications

DOI: 10.1038/s41467-025-63762-y